Patents by Inventor Mark Mills

Mark Mills has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • OX1 RECEPTOR ANTAGONISTS
    Publication number: 20260085056
    Abstract: The disclosures herein relate to novel compounds of formula (I); and salts thereof, wherein W; X; Y; Z; R1; R2; R3 and R4 are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of neurological or psychiatric disorders associated with orexin receptors.
    Type: Application
    Filed: May 9, 2025
    Publication date: March 26, 2026
    Applicant: NXERA PHARMA UK LIMITED
    Inventors: Giles Albert BROWN, Miles Stuart CONGREVE, John Andrew CHRISTOPHER, Nigel Alan SWAIN, Sarah Joanne BUCKNELL, Anne Mary STEPHENSON, Benjamin Gerald TEHAN, Mark MILLS, Anil PATEL
  • QUATERNARY INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTS
    Publication number: 20250214971
    Abstract: The present disclosure provides compounds of Formula I or II. Compounds of Formula I or II may be used in pharmaceutical formulations, and may be used for modulating glucocorticoid receptors.
    Type: Application
    Filed: November 13, 2024
    Publication date: July 3, 2025
    Inventors: Hazel Hunt, Lorna DUFFY, Ian STRUTT, Morgan JOUANNEAU, Thomas HORNSBY, Mark MILLS, Andrew William PHILLIPS, Jon-Paul WARD
  • Orexin 1 receptor antagonists
    Patent number: 12331029
    Abstract: The disclosures herein relate to novel compounds of formula (I): and salts thereof, wherein W; X; Y; Z; R1; R2; R3 and R4 are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of neurological or psychiatric disorders associated with orexin receptors.
    Type: Grant
    Filed: December 16, 2019
    Date of Patent: June 17, 2025
    Assignee: Nxera Pharma UK Limited
    Inventors: Giles Albert Brown, Miles Stuart Congreve, John Andrew Christopher, Nigel Alan Swain, Sarah Joanne Bucknell, Anne Mary Stephenson, Benjamin Gerald Tehan, Mark Mills, Anil Patel
  • BICYCLIC INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTS
    Publication number: 20250115583
    Abstract: The present disclosure provides compounds of Formula I, Ia, Ib, Ib-1, Ib-2, Ic, Ic-1, Id-1, and Id-2. Compounds of Formula I, Ia, Ib, Ib-1, Ib-2, Ic, Ic-1, Id-1, and Id-2 may be used in pharmaceutical formulations, and may be used for modulating glucocorticoid receptors.
    Type: Application
    Filed: July 5, 2024
    Publication date: April 10, 2025
    Inventors: Lorna Duffy, Thomas Hornsby, Morgan Jouanneau, Mark Mills, Andrew William Phillips, Andrew James Smith, Hazel Joan Hunt, Peter Hunt
  • PIPERAZINE INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTS
    Publication number: 20250092023
    Abstract: The present disclosure provides piperazine substituted fused azadecalin compounds of Formula J, I, Ia, Ib, Ib-1, Ib-2, Ic and Id for use in pharmaceutical formulations, and for modulating glucocorticoid receptors.
    Type: Application
    Filed: August 8, 2024
    Publication date: March 20, 2025
    Inventors: Mark Mills, Andrew William Phillips, Bohdan Waszkowycz, Hazel Joan Hunt, Angus Morrison, Angelo Pugliese, Jonathan Gillespie, Euan Fordyce
  • THIAZOLO[5,4-B]PYRIDINE MALT-1 INHIBITORS
    Publication number: 20250084099
    Abstract: The present disclosure provides for compounds of the general Formula (I) wherein R1a, R1b, R2, R3, R4, R5, R6, R7, R8, and Ring A have any of the values defined in the specification, and pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: April 18, 2024
    Publication date: March 13, 2025
    Inventors: Daniel Tzvi Cohen, Jane Gong, Tarun Jain, Puneet Kumar, Dachun Liu, Anthony Mastracchio, Mark Mills, Andrew William Phillips, John K. Pratt, Sreenivas Punna, Jennifer Ann Stockwell, Le Wang, Yiyun Yu
  • Oxexin 1 receptor antagonists
    Patent number: 12240825
    Abstract: The disclosures herein relate to novel compounds of formula (1) and salts thereof, wherein V; W; X; Y; Z; R1; R2; R3; R4 and R5 are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of neurological or psychiatric disorders associated with orexin receptors.
    Type: Grant
    Filed: January 28, 2020
    Date of Patent: March 4, 2025
    Assignee: NXERA PHARMA UK LIMITED
    Inventors: Giles Albert Brown, Miles Stuart Congreve, John Andrew Christopher, Nigel Alan Swain, Sarah Joanne Bucknell, Anne Mary Stephenson, Benjamin Gerald Tehan, Geraint Jones, Mark Mills, Anil Patel, Andrew William Phillips
  • Quaternary indazole glucocorticoid receptor antagonists
    Patent number: 12180186
    Abstract: The present disclosure provides compounds of Formula I or II. Compounds of Formula I or II may be used in pharmaceutical formulations, and may be used for modulating glucocorticoid receptors.
    Type: Grant
    Filed: August 11, 2023
    Date of Patent: December 31, 2024
    Assignee: Corcept Therapeutics Incorporated
    Inventors: Hazel Hunt, Lorna Duffy, Ian Strutt, Morgan Jouanneau, Thomas Hornsby, Mark Mills, Andrew William Phillips, Jon-Paul Ward
  • Bicyclic indazole glucocorticoid receptor antagonists
    Patent number: 12098141
    Abstract: The present disclosure provides compounds of Formula I, Ia, Ib, Ib-1, Ib-2, Ic, Ic-1, Id-1, and Id-2. Compounds of Formula I, Ia, Ib, Ib-1, Ib-2, Ic, Ic-1, Id-1, and Id-2 may be used in pharmaceutical formulations, and may be used for modulating glucocorticoid receptors.
    Type: Grant
    Filed: December 20, 2022
    Date of Patent: September 24, 2024
    Assignee: Corcept Therapeutics Incorporated
    Inventors: Lorna Duffy, Thomas Hornsby, Morgan Jouanneau, Mark Mills, Andrew William Phillips, Andrew James Smith, Hazel Joan Hunt, Peter Hunt
  • Piperazine indazole glucocorticoid receptor antagonists
    Patent number: 12098144
    Abstract: Provided are piperazine substituted fused azadecalin compounds of Formula J, I, Ia, Ib, Ib-1, Ib-2, Ic and Id for use in pharmaceutical formulations, and for modulating glucocorticoid receptors.
    Type: Grant
    Filed: December 20, 2022
    Date of Patent: September 24, 2024
    Assignee: Corcept Therapeutics Incorporated
    Inventors: Mark Mills, Andrew William Phillips, Bohdan Waszkowycz, Hazel Joan Hunt, Angus Morrison, Angelo Pugliese, Jonathan Gillespie, Euan Fordyce
  • Thiazolo[5,4-b]pyridine MALT-1 inhibitors
    Patent number: 11993613
    Abstract: The present disclosure provides for compounds of the general Formula (I) wherein R1a, R1b, R2, R3, R4, R5, R6, R7, R8, and Ring A have any of the values defined in the specification, and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: March 30, 2023
    Date of Patent: May 28, 2024
    Assignee: AbbVie Inc.
    Inventors: Puneet Kumar, Anthony Mastracchio, Mark Mills, Andrew William Phillips
  • QUATERNARY INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTS
    Publication number: 20240150320
    Abstract: The present disclosure provides compounds of Formula I or II. Compounds of Formula I or II may be used in pharmaceutical formulations, and may be used for modulating glucocorticoid receptors.
    Type: Application
    Filed: August 11, 2023
    Publication date: May 9, 2024
    Inventors: Hazel Hunt, Lorna DUFFY, Ian STRUTT, Morgan JOUANNEAU, Thomas HORNSBY, Mark MILLS, Andrew William PHILLIPS, Jon-Paul WARD
  • Quaternary indazole glucocorticoid receptor antagonists
    Patent number: 11787780
    Abstract: The present disclosure provides compounds of Formula I or II. Compounds of Formula I or II may be used in pharmaceutical formulations, and may be used for modulating glucocorticoid receptors.
    Type: Grant
    Filed: June 21, 2021
    Date of Patent: October 17, 2023
    Assignee: Corcept Therapeutics Incorporated
    Inventors: Hazel Hunt, Lorna Duffy, Ian Strutt, Morgan Jouanneau, Thomas Hornsby, Mark Mills, Andrew William Phillips, Jon-Paul Ward
  • THIAZOLO[5,4-B]PYRIDINE MALT-1 INHIBITORS
    Publication number: 20230312601
    Abstract: The present disclosure provides for compounds of the general Formula (I) wherein R1a, R1b, R2, R3, R4, R5, R6, R7, R8, and Ring A have any of the values defined in the specification, and pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: March 30, 2023
    Publication date: October 5, 2023
    Inventors: Daniel Cohen, Jane Gong, Tarun Jain, Puneet Kumar, Dachun Liu, Anthony Mastracchio, Mark Mills, Andrew William Phillips, John K. Pratt, Sreenivas Punna, Jennifer Ann Stockwell, Le Wang, Yiyun Yu
  • BICYCLIC INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTS
    Publication number: 20230242514
    Abstract: The present disclosure provides compounds of Formula I, Ia, Ib, Ib-1, Ib-2, Ic, Ic-1, Id-1, and Id-2. Compounds of Formula I, Ia, Ib, Ib-1, Ib-2, Ic, Ic-1, Id-1, and Id-2 may be used in pharmaceutical formulations, and may be used for modulating glucocorticoid receptors.
    Type: Application
    Filed: December 20, 2022
    Publication date: August 3, 2023
    Inventors: Lorna Duffy, Thomas Hornsby, Morgan Jouanneau, Mark Mills, Andrew William Phillips, Andrew James Smith, Hazel Joan Hunt, Peter Hunt
  • PIPERAZINE INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTS
    Publication number: 20230192666
    Abstract: The present disclosure provides piperazine substituted fused azadecalin compounds of Formula J, I, Ia, Ib, Ib-1, Ib-2, Ic and Id for use in pharmaceutical formulations, and for modulating glucocorticoid receptors.
    Type: Application
    Filed: December 20, 2022
    Publication date: June 22, 2023
    Inventors: Mark Mills, Andrew William Phillips, Bohdan Waszkowycz, Hazel Joan Hunt, Angus Morrison, Angelo Pugliese, Jonathan Gillespie, Euan Fordyce
  • QUATERNARY INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTS
    Publication number: 20230032612
    Abstract: The present disclosure provides compounds of Formula I or II. Compounds of Formula I or II may be used in pharmaceutical formulations, and may be used for modulating glucocorticoid receptors.
    Type: Application
    Filed: June 21, 2021
    Publication date: February 2, 2023
    Inventors: Hazel Hunt, Lorna DUFFY, Ian STRUTT, Morgan JOUANNEAU, Thomas HORNSBY, Mark MILLS, Andrew William PHILLIPS, Jon-Paul WARD
  • OXEXIN 1 RECEPTOR ANTAGONISTS
    Publication number: 20220098165
    Abstract: The disclosures herein relate to novel compounds of formula (1) and salts thereof, wherein V; W; X; Y; Z; R1; R2; R3; R4 and R5 are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of neurological or psychiatric disorders associated with orexin receptors.
    Type: Application
    Filed: January 28, 2020
    Publication date: March 31, 2022
    Inventors: Giles Albert Brown, Miles Stuart Congreve, John Andrew Christopher, Nigel Alan Swain, Sarah Joanne Bucknell, Anne Mary Stephenson, Benjamin Gerald Tehan, Geraint Jones, Mark Mills, Anil Patel, Andrew William Phillips
  • OREXIN 1 RECEPTOR ANTAGONISTS
    Publication number: 20220041573
    Abstract: The disclosures herein relate to novel compounds of formula (I): and salts thereof, wherein W; X; Y; Z; R1; R2; R3 and R4 are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of neurological or psychiatric disorders associated with orexin receptors.
    Type: Application
    Filed: December 16, 2019
    Publication date: February 10, 2022
    Applicants: Heptares Therapeutics Limited, Heptares Therapeutics Limited
    Inventors: Giles Albert Brown, Miles Stuart Congreve, John Andrew Christopher, Nigel Alan Swain, Sarah Joanne Bucknell, Anne Mary Stephenson, Benjamin Gerald Tehan, Mark Mills, Anil Patel
  • OX1 ANTAGONISTS
    Publication number: 20210179578
    Abstract: The disclosures herein relate to novel compounds of formula (1) and salts thereof, wherein X; Y; R1; R2; R3; R4; R5; R6; R7 and R8 are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of neurological or psychiatric disorders associated with orexin receptors.
    Type: Application
    Filed: November 5, 2018
    Publication date: June 17, 2021
    Inventors: John Andrew Christopher, Sarah Joanne Bucknell, Miles Stuart Congreve, Benjamin Gerald Tehan, Rebecca Helen Nonoo, Giles Albert Brown, Nigel Alan Swain, Mark Mills